EFFECT OF THE CALCIUM-ANTAGONIST, NIFEDIPINE, ON ISCHEMIC RETINAL DYSFUNCTION

被引：52

作者：

CROSSON, CE

WILLIS, JA

POTTER, DE

机构：

[1] Houston Biotechnology, Incorportaed, The Woodlands, Texas

[2] Department of Ophthalmology, Texas Tech University, Lubbock, Texas

[3] Warehouse School of Medicine, Atlanta

来源：

JOURNAL OF OCULAR PHARMACOLOGY | 1990年 / 6卷 / 04期

关键词：

D O I：

10.1089/jop.1990.6.293

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The therapeutic effectiveness of calcium channel antagonists (CCA) in hypertension and angina are well established. More recently, CCAs have also been demonstrated to ameliorate neurologic dysfunction that often accompanies ischemia associated with subarachnoid hemorrhage and stroke. We have hypothesized that retinal degeneration associated with ischemia may also result from the accumulation of calcium intracellularly, so-called "Ca++ overload". To test this hypothesis, a rat model of acute retinal ischemia, produced by direct occlusion of posterior ciliary and central retinal arteries, was developed. The extent of retinal dysfunction induced by ischemia was evaluated by electroretinograms (ERGs). Occlusion of the retinal arteries resulted in the disappearance ob both a- and b-waves during the occlusion period (30 minutes) in vehicle-treated rats. Total retinal ischemia did not produce any significant change in magnitude of ERG a-wave amplitude during three-hours of reperfusion. However, ERG b-waves amplitudes were significantly reduced by more than 60%. In rats, pretreatment with nifedipine (0.33 to 3.3 mg/kg, i.p.) 30 minutes prior to the occlusion of the retinal vessels produced a significant dose-dependent increase in the recovery of b-wave amplitude when compared to vehicle-treated rats. These data support the idea that "Ca++ overload", resulting from the deregulation of intracellular Ca++ homeostasis, is a primary factor involved in ischemic retinal degeneration and that CCAs can protect the retina from ischemic damage.

引用

页码：293 / 299

页数：7

共 10 条

[1] Boddeck E., Hugtenburg J., Jap W., Heynis J., van Zwieten P., New anti-ischemic drugs: cytoprotective action with no primary hemodynamic effects, TIPS, 10, pp. 397-400, (1989)
[2] Godfraind T., Towse G., Van Nueten J.M., Cinnarizine - a selective calcium entry blocker, Drugs of Today, 228, pp. 27-42, (1982)
[3] Newberg L.A., Steen P.A., Milde J.H., Gisvold S.E., Lanier W.C., Effect of nimodipine on cerebral blood flow follow complete global ischemia in dogs and primates, In First International Nimotop Symposium - Stuttart, Schattauer, pp. 99-104, (1984)
[4] Gelmers H.J., Gorter K., de Weerdt C.J., Wierer H.J.A., A controlled trial of nimodipine in acute ischemic stroke, N. Engl. J. Med, 318, pp. 203-207, (1988)
[5] Stefansson E., Wilson C.A., Schoen T., Kuwabara T., Experimental ischemic induces cell mitosis in the adult rat retina, Invest. Ophthalmol. Vis. Sci, 29, pp. 1050-1055, (1988)
[6] Yoon Y.H., Marmor M.F., Dextromethorphan protects retina against ischemic injury in vivo, Arch. Ophthamol, 107, pp. 409-411, (1989)
[7] Olney J.W., Price M.T., Fuller T.A., The anti-excitotoxic effects of certain anesthetics analgesics and sedative-hypnotics, Neurosci Letters, 68, pp. 29-34, (1986)
[8] David P., Lusky M., Teichberg V.I., Involvement of excitatory neurotransmitters in the damage produced in chick embryo retinas by anoxia and extracellular high potassium, Exp. Eye Res, 46, pp. 651-662, (1988)
[9] Crosson C.E., Willis J.A., Potter D.E., Does dextromethorphan prevent ischemic retinal dysfunction by NMDA receptor antagonism? Invest, Ophthalmol. Vis. Sci. (Suppl), 34, 385, (1990)
[10] Carpenter C.L., Marks S.S., Watson D.L., Greenberg A., Dextromethorphan and dextrorphan as calcium channel antagonists, Brain Res, 439, pp. 372-375, (1988)

← 1 →